PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-322

Alzheimer's Disease Therapeutic Market to reach USD $30.8 Billion by 2033.



I hope the SAB have read and provided analysis back to PAA board & management on this study.
Perhaps this, along with stellar MND/ALS results, were the catalyst to the changes to the board , with a clarity and focus around neurodegenerative disease.

PharmAust & MPL becomes a beast - strong safety profile, proven to traverse the blood brain barrier, proving to be efficacious against MND/ALS - an untreated condition, granted ODD by the FDA - and with a pre-clinical trial indicating strong potential against Alzheimer's Disease - a massive market.

Goodness ... just get the board & management demonstrating they are ready & capable to embrace and execute against this enormous opportunity and we are off to the races.

DYOR
IMO